Table 1

Demographics and clinical characteristics of the study population

VariablePsA (N=203)PsC (N=155)p Value
Age (years), mean±SD51.6 (13)50.3 (12.4)0.33
Sex: female80 (39.4%)68 (43.9%)0.39
Age at onset of psoriasis (years), mean±SD26.5 (13.1)30.7 (16.9)0.01
Age at onset of PsA (years), mean±SD37 (12.8)
Ethnicity: Caucasian176 (87.1%)128 (82.6%)0.23
Alcohol consumption: daily15 (7.4%)20 (12.9%)0.001
 Social95 (46.8%)89 (57.4%)
Smoker: current23 (11.3%)31 (20%)0.06
 Past smoker51 (25.1%)46 (29.7%)
Active joint count, mean±SD4.6 (7.8)
Damaged joint count, mean±SD7.6 (12.3)
PASI, current, mean±SD3.6 (5.5)5.3 (5.3)0.003
 SBP (mm Hg), mean±SD124 (16.9)120 (16.5)0.07
 DBP (mm Hg), mean±SD77.8 (8.9)77.4 (9.6)0.75
Anti-hypertensive medications65 (32%)33 (21.9%)0.02
 Hypertension119 (58.6%)73 (47.1%)0.03
 Glucose, mean±SD5.5 (1.5)5.2 (1.3)0.12
Anti-diabetes medications24 (11.8%)8 (5.2%)0.03
Impaired glucose tolerance63 (31%)32 (20.7%)0.02
 Total cholesterol (mmol/l), mean±SD5 (1.1)5.2 (1.3)0.45
 Triglycerides (mmol/l), mean±SD1.4 (0.9)1.5 (1.1)0.55
 Abnormal triglycerides73 (36%)50 (32.3%)0.46
 HDL (mmol/l), mean±SD1.4 (0.5)1.3 (0.4)0.69
 Abnormal HDL50 (24.6%)43 (27.7%)0.51
 LDL (mmol/l), mean±SD3 (0.9)3.1 (0.9)0.52
 Lipid-lowering medications37 (18.2%)20 (12.9%)0.17
 BMI (kg/m2), mean±SD29.5 (6.6)28.2 (5.5)0.05
BMI>3081 (40.7%)45 (29.8%)0.04
 Abdominal obesity*101 (50.3%)65 (41.9%)0.12
hsCRP (mg/l), mean±SD12.3 (24.4)4.3 (13.1)<0.001
NSAID, current use121 (59.6%)10 (6.5%)<0.001
DMARD, current use117 (57.6%)18 (11.6%)<0.001
Anti-TNFα agents, current use82 (40.4%)11 (7.1%)<0.001
Prednisone, current use7 (3.4%)00.02
  • *Waist circumference ≥88 cm for women and ≥102 for men.

  • BMI, body mass index; DBP, diastolic blood pressure; DMARD, disease-modifying antirheumatic drug; HDL, high-density lipoprotein; hsCRP, high sensitivity C-reactive protein; LDL, low-density lipoprotein; PASI, psoriasis area and severity index; PsA, psoriatic arthritis; PsC, cutaneous psoriasis without arthritis; SBP, systolic blood pressure; TNFα, tumour necrosis factor α.